Editorial for “Association Between the Systemic Immune‐Inflammation Index and Aneurysmal Wall Enhancement on High‐Resolution Magnetic Resonance Vessel Wall Imaging in Unruptured Intracranial Aneurysms”

Unruptured intracranial aneurysms (UIAs) are common—affecting approximately 3%–7% of the general population—and represent the precursor state of aneurysmal subarachnoid hemorrhage, a neurological emergency associated with high mortality and long-term disability 1, 2. Their clinical significance lies in the difficulty of determining which aneurysms will remain stable and which are at risk for growth or rupture. Rupture risk varies substantially depending on patient-specific and aneurysm-specific factors. Although UIAs are often detected incidentally on CTA or MRA, established risk factors such as hypertension, smoking, older age, aneurysm size ≥ 7 mm, irregular morphology, and posterior circulation location elevate rupture risk. Because many UIAs never rupture while others rupture unpredictably with devastating consequences, clinicians must carefully balance the morbidity associated with intervention against the natural history of each lesion. The natural history of UIAs—particularly small aneurysms—remains poorly characterized. Most existing risk prediction tools rely on retrospective data, and well-validated prospective longitudinal studies are lacking. Commonly used models such as PHASES and ELAPSS place substantial weight on aneurysm size and location relative to other clinical variables, limiting their usefulness in patients with small or anterior-circulation aneurysms 3, 4. Advanced imaging techniques, including vessel wall MRI, have emerged as promising tools for identifying aneurysms at risk of rupture. Because inflammation may be a central component of aneurysm pathophysiology, aneurysm wall enhancement (AWE) has been associated with increased instability 2. In parallel, blood-based inflammatory markers such as the systemic immune-inflammation index (SII) have recently gained interest as potential predictors of aneurysm behavior 5. SII offers practical advantages: it is easily accessible, potentially more objective, and less labor-intensive than advanced imaging. In this cross-sectional study of 418 UIAs, the authors found that SII—a biomarker derived from routine blood counts (platelets × neutrophils/lymphocytes)—is independently associated with both AWE and aneurysm growth (odds ratios 1.93 and 24.61, respectively) 6. These associations persisted after multivariable adjustment and propensity score matching. Additionally, SII correlated significantly with aneurysm location. Collectively, these findings support SII as a promising, cost-effective biomarker that may reflect underlying inflammatory activity and help identify UIAs at higher risk of instability. However, important limitations must be acknowledged. This was a retrospective study, and its use of surrogate endpoints—AWE and aneurysm growth—limits direct conclusions about rupture risk. While practical, surrogate markers do not fully substitute for the clinically meaningful outcome of aneurysm rupture, and correlation with AWE alone may not translate to a definitive increase in rupture risk. By demonstrating that a readily accessible blood-based biomarker correlates with two markers of aneurysm instability, this study provides clinicians with a practical adjunct to current risk stratification tools. SII may be particularly useful for patients whose rupture risk falls into an intermediate category—those who do not meet conventional criteria for intervention yet have clinical or imaging features that raise concern. Examples include patients with anterior-circulation aneurysms < 7 mm who are younger, actively smoking, or have risky imaging features. Similarly, treatment decisions in elderly adults with aneurysms 7–12 mm can be challenging because procedural risks must be weighed against life expectancy and comorbidities. SII may help refine risk estimates in such nuanced clinical contexts. SII may also have utility in patients with high-risk aneurysms managed conservatively, where surveillance intervals for imaging are not well defined. Because changes in AWE may lag behind biological processes, SII could complement imaging by offering more dynamic monitoring. In short, incorporation of SII into clinical decision-making may enhance risk stratification, support more personalized surveillance strategies, and help avoid unnecessary interventions in patients with low-risk profiles. Despite its promise, SII has important limitations. Its influence on treatment decisions may be modest, as clinicians often prioritize aneurysm size when considering intervention regardless of biomarker status. Because SII reflects systemic inflammation, it may capture only one aspect of aneurysm pathophysiology and does not account for biomechanical or hemodynamic factors. In patients with multiple aneurysms, SII offers no lesion-specific localization, and unrecognized inflammatory processes may lead to false-positive elevations and misinterpretation. Future prospective studies are needed to determine whether SII is causally related to aneurysm rupture and whether reducing SII through conservative management strategies leads to lower rupture risk. Patient-reported outcomes are another important domain: correlations between SII and UIA symptoms (e.g., headache or visual changes) may refine clinical assessment and understanding how patients perceive and act upon an abstract, non-visual biomarker could affect shared decision-making. Ultimately, establishing whether SII can contribute to truly personalized, biology-informed management will require integration of biomarker data, imaging features, and patient-centered factors. This work was supported by the National Heart, Lung, and Blood Institute (R01HL162743).